Health Service Executive

Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland.

Documents

Documents published by the Health Service Executive, containing at least one indication involving a biomarker.

Name	Indications	Statements
Afatinib Monotherapy. NCCP National SACT Regimen. HSE.	1	1
Alectinib Monotherapy. NCCP National SACT Regimen. HSE.	2	2
Asciminib Monotherapy. NCCP National SACT Regimen. HSE.	1	1
Bosutinib Monotherapy. NCCP National SACT Regimen. HSE.	1	1
Brigatinib Therapy. NCCP National SACT Regimen. HSE.	2	2
Ceritinib Monotherapy. NCCP National SACT Regimen. HSE.	1	1
Cobimetinib and Vemurafenib Therapy. NCCP National SACT Regimen. HSE.	1	2
Crizotinib Monotherapy. NCCP National SACT Regimen. HSE.	1	1
Dabrafenib Monotherapy. NCCP National SACT Regimen. HSE.	1	2
Dacomitinib Monotherapy. NCCP National SACT Regimen. HSE.	1	1
Encorafenib and Binimetinib Therapy. NCCP National SACT Regimen. HSE.	1	2
Entrectinib Therapy. NCCP National SACT Regimen. HSE.	1	1
Lorlatinib Therapy. NCCP National SACT Regimen. HSE.	2	2
Midostaurin, DAUNOrubicin and Cytarabine Induction Therapy. NCCP National SACT Regimen. HSE.	1	1
Neratinib Therapy. NCCP National SACT Regimen. HSE.	1	6
Niraparib and Abiraterone acetate (Akeega) and prednisoLONE Therapy. NCCP National SACT Regimen. HSE.	1	3
Olaparib (Tablet) and Bevacizumab Therapy. NCCP National SACT Regimen. HSE.	1	14
Olaparib (Tablet) Monotherapy. NCCP National SACT Regimen. HSE.	3	28
Osimertinib Monotherapy. NCCP National SACT Regimen. HSE.	3	4
PONATinib Therapy. NCCP National SACT Regimen. HSE.	2	3
Talazoparib Therapy. NCCP National SACT Regimen. HSE.	1	2
Trametinib and Dabrafenib Therapy. NCCP National SACT Regimen. HSE.	2	4
Vemurafenib Monotherapy. NCCP National SACT Regimen. HSE.	1	2
Venetoclax Monotherapy 2021, version number 3, NCCP National SACT Regimen, NCCP, viewed 18/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/400.pdf. NCCP National SACT Regimen. HSE.	2	4
Zanubrutinib Therapy. NCCP National SACT Regimen. HSE.	1	3
Acalabrutinib (Tablets) Monotherapy. NCCP National SACT Regimen. HSE.	1	3
Ibrutinib Therapy CLL / Waldenstroms Macroglobulinaemia. NCCP National SACT Regimen. HSE.	1	3
Idelalisib and riTUXimab Therapy. NCCP National SACT Regimen. HSE.	1	3
Nivolumab 3mg/kg with Ipilimumab 1mg/kg Therapy. NCCP National SACT Regimen. HSE.	1	2
Pembrolizumab 200mg Monotherapy. NCCP National SACT Regimen. HSE.	5	7
Larotrectinib Monotherapy - Paediatric. NCCP National SACT Regimen. HSE.	1	3
Larotrectinib Monotherapy - Adult. NCCP National SACT Regimen. HSE.	1	3
Gefitinib Monotherapy. NCCP National SACT Regimen. HSE.	1	1
Erlotinib Therapy. NCCP National SACT Regimen. HSE.	2	2
Trastuzumab Emtansine (Kadcyla) - 21 days. NCCP National SACT Regimen. HSE.	1	1
Palbociclib Therapy - 28 day. NCCP National SACT Regimen. HSE.	2	6
Ribociclib Therapy - 28 day. NCCP National SACT Regimen. HSE.	2	9
Inotuzumab Ozogamicin Monotherapy. NCCP National SACT Regimen. HSE.	1	2
Blinatumomab Paediatric Therapy. NCCP National SACT Regimen. HSE.	1	1
Brentuximab vedotin, Etoposide, methylPREDNISolone, Cytarabine and CISplatin, (ESHAP) therapy (BRESHAP). NCCP National SACT Regimen. HSE.	1	1
Pertuzumab and Trastuzumab and Chemotherapy Therapy - 21 day cycle. NCCP National SACT Regimen. HSE.	2	7
Gemtuzumab ozogamicin DAUNOrubicin and cytarabine Therapy (AML induction). NCCP National SACT Regimen. HSE.	1	1
Pembrolizumab, PEMEtrexed and CARBOplatin (AUC 5) Therapy. NCCP National SACT Regimen. HSE.	1	1
Pembrolizumab, PEMEtrexed and CISplatin Therapy. NCCP National SACT Regimen. HSE.	1	1
Durvalumab Monotherapy 10mg/kg - 14 Day. NCCP National SACT Regimen. HSE.	1	1
Atezolizumab Monotherapy. NCCP National SACT Regimen. HSE.	4	6
Trastuzumab Emtansine (Kadcyla) Early Breast Cancer Therapy - 21 days. NCCP National SACT Regimen. HSE.	1	1
Pembrolizumab, CARBOplatin (AUC 5) and 5-Fluorouracil Therapy. NCCP National SACT Regimen. HSE.	1	1
Pembrolizumab, Cisplatin and 5-Fluorouracil Therapy. NCCP National SACT Regimen. HSE.	1	1
Nivolumab, ipilimumab, CARBOplatin and PACLitaxel Therapy. NCCP National SACT Regimen. HSE.	1	1
Nivolumab, ipilimumab, PEMEtrexed and CARBOplatin Therapy. NCCP National SACT Regimen. HSE.	1	1
Nivolumab, ipilimumab, PEMEtrexed and CISplatin Therapy. NCCP National SACT Regimen. HSE.	1	1
Atezolizumab and nab-PACLitaxel Therapy. NCCP National SACT Regimen. HSE.	1	1
Blinatumomab Therapy (ALL with MRD >= 0.1%). NCCP National SACT Regimen. HSE.	1	1
Blinatumomab for Relapsed Paediatric ALL: Consolidation Therapy. NCCP National SACT Regimen. HSE.	1	1
Pertuzumab and Trastuzumab (Phesgo), PACLitaxel and CARBOplatin Therapy (TRAIN-2). NCCP National SACT Regimen. HSE.	1	1
Brentuximab vedotin Monotherapy. NCCP National SACT Regimen. HSE.	4	4
Brentuximab vedotin and ICE Therapy. NCCP National SACT Regimen. HSE.	1	1
Pembrolizumab 200mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy. NCCP National SACT Regimen. HSE.	1	2
Nivolumab 480mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy. NCCP National SACT Regimen. HSE.	1	1
Atezolizumab 1680mg Monotherapy - 28 Day. NCCP National SACT Regimen. HSE.	4	6
Pembrolizumab and FOLFOX-6 Modified Therapy. NCCP National SACT Regimen. HSE.	1	1
Blinatumomab Therapy. NCCP National SACT Regimen. HSE.	1	1
Pertuzumab/Trastuzumab (Phesgo) and Weekly PACLitaxel Therapy - 21 day cycle. NCCP National SACT Regimen. HSE.	1	1
Pertuzumab,Trastuzumab and Weekly PACLitaxel Therapy - 21 day cycle. NCCP National SACT Regimen. HSE.	1	1
Pertuzumab/Trastuzumab (Phesgo) and DOCEtaxel Therapy - 21 day cycle. NCCP National SACT Regimen. HSE.	1	1
Pertuzumab,Trastuzumab and DOCEtaxel Therapy - 21 day cycle. NCCP National SACT Regimen. HSE.	1	1
Pertuzumab/Trastuzumab (Phesgo) and Vinorelbine. NCCP National SACT Regimen. HSE.	1	1
Pertuzumab, Trastuzumab, and Vinorelbine. NCCP National SACT Regimen. HSE.	1	1
Pertuzumab/Trastuzumab (Phesgo) Maintenance Therapy. NCCP National SACT Regimen. HSE.	1	1
DOCEtaxel, CARBOplatin, Trastuzumab and Pertuzumab (TCHP) Therapy. NCCP National SACT Regimen. HSE.	1	1
Nivolumab 360mg and Chemotherapy. NCCP National SACT Regimen. HSE.	1	5
Pembrolizumab 200mg, weekly CARBOplatin AUC 1.5 and PACLitaxel 80mg/m 2 followed by DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy. NCCP National SACT Regimen. HSE.	1	1
Trastuzumab (IV) Monotherapy - 21 days. NCCP National SACT Regimen. HSE.	2	2
Trastuzumab (IV) Monotherapy - 7 days. NCCP National SACT Regimen. HSE.	1	1
Bevacizumab 10mg/kg - 14 days. NCCP National SACT Regimen. HSE.	1	1
Bevacizumab 15mg/kg Therapy - 21 days. NCCP National SACT Regimen. HSE.	2	2
Capecitabine Monotherapy. NCCP National SACT Regimen. HSE.	1	1
Lapatinib and Capecitabine Therapy. NCCP National SACT Regimen. HSE.	1	1
Tamoxifen Monotherapy. NCCP National SACT Regimen. HSE.	2	2
Anastrozole Monotherapy. NCCP National SACT Regimen. HSE.	3	9
DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 days. NCCP National SACT Regimen. HSE.	1	1
Trastuzumab Subcutaneous 21 days - Metastatic Breast Cancer. NCCP National SACT Regimen. HSE.	4	6
Trastuzumab Subcutaneous 21 days - Early Breast Cancer. NCCP National SACT Regimen. HSE.	4	5
Everolimus and Exemestane Therapy. NCCP National SACT Regimen. HSE.	1	3
CARBOplatin (AUC 6) and Weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin cycloPHOSphamide Therapy-Triple Negative Breast Cancer Therapy. NCCP National SACT Regimen. HSE.	1	1
Fulvestrant Therapy. NCCP National SACT Regimen. HSE.	2	2
Letrozole Monotherapy. NCCP National SACT Regimen. HSE.	4	12
Exemestane Monotherapy. NCCP National SACT Regimen. HSE.	1	3
Gemcitabine and CARBOplatin (AUC2) Therapy - 21 days. NCCP National SACT Regimen. HSE.	1	1
DOXOrubicin, cycloPHOSphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH). NCCP National SACT Regimen. HSE.	2	2
PACLitaxel (80) and Trastuzumab Therapy - 7 day (12 weeks). NCCP National SACT Regimen. HSE.	1	1
Abemaciclib Therapy. NCCP National SACT Regimen. HSE.	1	12
Pertuzumab and Trastuzumab Therapy. NCCP National SACT Regimen. HSE.	1	1
DOCEtaxel, CARBOplatin, Trastuzumab (S/C) and Pertuzumab (TCH(S/C)P) Therapy. NCCP National SACT Regimen. HSE.	1	1
CARBOplatin (AUC 2) weekly and PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin cycloPHOSphamide Therapy - Triple Negative Breast Cancer Therapy. NCCP National SACT Regimen. HSE.	1	1
Pertuzumab, Trastuzumab, PACLitaxel and CARBOplatin Therapy (TRAIN-2). NCCP National SACT Regimen. HSE.	1	1
DOCEtaxel, CARBOplatin and Pertuzumab/Trastuzumab (Phesgo)(TCHP) Therapy. NCCP National SACT Regimen. HSE.	1	1
Pembrolizumab 200mg, CARBOplatin AUC 5 and weekly PACLitaxel 80mg/m 2 followed by DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy. NCCP National SACT Regimen. HSE.	1	1
Dose Dense DOXOrubicin, cycloPHOSphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (DD AC-TH). NCCP National SACT Regimen. HSE.	2	2
Cetuximab Therapy-7 day. NCCP National SACT Regimen. HSE.	1	1
Panitumumab 6mg/kg Therapy. NCCP National SACT Regimen. HSE.	1	1
Cetuximab (7 days) and FOLFIRI (14 days) Therapy. NCCP National SACT Regimen. HSE.	1	1
Cetuximab (7 days) and Irinotecan (14 days) Therapy. NCCP National SACT Regimen. HSE.	1	1
Cetuximab (14 days) and Irinotecan (14 days) Therapy. NCCP National SACT Regimen. HSE.	1	1
Panitumumab 6mg/kg and Modified FOLFOX-6 Therapy - 14 day. NCCP National SACT Regimen. HSE.	1	1
Panitumumab 6mg/kg and FOLFIRI Therapy-14 day. NCCP National SACT Regimen. HSE.	2	2
Trastuzumab 5-Fluorouracil and CISplatin Therapy - 21 days. NCCP National SACT Regimen. HSE.	1	1
Cetuximab (14 days) and FOLFIRI (14 days) Therapy. NCCP National SACT Regimen. HSE.	1	1
Nivolumab 240mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy. NCCP National SACT Regimen. HSE.	1	1
Nivolumab and FOLFOX-6 Modified Therapy. NCCP National SACT Regimen. HSE.	1	1
Pembrolizumab 400mg Monotherapy. NCCP National SACT Regimen. HSE.	5	5
Pembrolizumab, PACLitaxel 175mg/m2, CARBOplatin AUC 5 and Bevacizumab Therapy. NCCP National SACT Regimen. HSE.	1	1
Pembrolizumab, PACLitaxel 175mg/m2 and CARBOplatin AUC 5 Therapy. NCCP National SACT Regimen. HSE.	1	1
Idelalisib and Ofatumumab Therapy. NCCP National SACT Regimen. HSE.	1	3
Midostaurin Maintenance Therapy. NCCP National SACT Regimen. HSE.	1	1
Midostaurin and Intermediate Dose Cytarabine Consolidation Therapy. NCCP National SACT Regimen. HSE.	1	1
Gemcitabine (1250mg/m2) and CISplatin (75mg/m2) Therapy - 21 day. NCCP National SACT Regimen. HSE.	1	1
CARBOplatin (AUC 6) and PACLitaxel 200mg/m2 Therapy. NCCP National SACT Regimen. HSE.	1	1
Gemcitabine (1000mg/m2) and CARBOplatin (AUC 5) Therapy - 21 day. NCCP National SACT Regimen. HSE.	1	1
PEMEtrexed and CISplatin Therapy. NCCP National SACT Regimen. HSE.	1	1
PEMEtrexed and CARBOplatin Therapy. NCCP National SACT Regimen. HSE.	1	1
Atezolizumab 840mg Monotherapy - 14 Day. NCCP National SACT Regimen. HSE.	3	4
Durvalumab Monotherapy 1500 mg - 28 day. NCCP National SACT Regimen. HSE.	1	1
(*riTUXimab) cycloPHOSphamide, DOXOrubicin, vinCRIStine and prednisoLONE (*R)-CHOP) Therapy - 21 days. NCCP National SACT Regimen. HSE.	1	1
RiTUXimab and Bendamustine Therapy. NCCP National SACT Regimen. HSE.	2	2
(R*)-DHAP Therapy. NCCP National SACT Regimen. HSE.	1	1
Dose Adjusted riTUXimab, Etoposide, prednisoLONE, DOXOrubicin, cycloPHOSphamide and vinCRIStine (DA-R EPOCH) Therapy. NCCP National SACT Regimen. HSE.	1	2
(R*)-ICE ((riTUXimab), Ifosfamide, CARBOplatin and Etoposide) Therapy. NCCP National SACT Regimen. HSE.	1	1
(*riTUXimab) cycloPHOSphamide, DOXOrubicin, vinCRIStine and prednisoLONE (*R)-CHOP Therapy - 14 day. NCCP National SACT Regimen. HSE.	1	1
(R*)- miniCHOP Therapy - 21 days. NCCP National SACT Regimen. HSE.	1	1
R-Gemcitabine (1000mg/m2) Oxaliplatin Therapy - 14 day. NCCP National SACT Regimen. HSE.	1	2
R-CEOP Therapy - 21 days. NCCP National SACT Regimen. HSE.	1	1
Brentuximab vedotin and Bendamustine Therapy. NCCP National SACT Regimen. HSE.	1	1
riTUXimab 375 mg/m2 Combination Therapy-21 day. NCCP National SACT Regimen. HSE.	1	4
RiTUXimab 375 mg/m2 Maintenance Therapy- 56 day. NCCP National SACT Regimen. HSE.	1	2
riTUXimab (S/C 1400mg) Maintenance Therapy-84 day. NCCP National SACT Regimen. HSE.	1	2
riTUXimab (S/C 1400mg) Maintenance Therapy-56 day. NCCP National SACT Regimen. HSE.	1	2
Dose Adjusted riTUXimab S/C, Etoposide, prednisoLONE, DOXOrubicin, cycloPHOSphamide and vinCRIStine. NCCP National SACT Regimen. HSE.	1	2
riTUXimab, Cyclophosphamide, vinCRIStine and prednisoLONE R-CVP Therapy-21 days. NCCP National SACT Regimen. HSE.	2	2
RiTUXimab 375 mg/m2 Maintenance Therapy-84 day. NCCP National SACT Regimen. HSE.	1	2
Imatinib Therapy - GIST. NCCP National SACT Regimen. HSE.	2	2
Tepotinib Therapy. NCCP National SACT Regimen. HSE.	1	2
Trastuzumab Deruxtecan (Enhertu) Therapy. NCCP National SACT Regimen. HSE.	1	1
Pembrolizumab 400mg, CARBOplatin AUC 5 and weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy. NCCP National SACT Regimen. HSE.	1	1
Pembrolizumab 400mg, Weekly CARBOplatin AUC 1.5 and PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy. NCCP National SACT Regimen. HSE.	1	1
Vandetanib Therapy. NCCP National SACT Regimen. HSE.	1	1
Trentinoin (ATRA) and Arsenic Trioxide (ATO) Induction Therapy. NCCP National SACT Regimen. HSE.	2	2
Sacituzumab Govitecan Therapy. NCCP National SACT Regimen. HSE.	1	1
Entrectinib Monotherapy - Adult. NCCP National SACT Regimen. HSE.	1	3

Regulatory approvals

Approved indications from the Health Service Executive for cancer drugs containing at least one biomarker.

Document	Indication	Statements
Afatinib Monotherapy. NCCP National SACT Regimen. HSE.	Treatment of Epidermal Growth Factor Receptor (EGFR) TKI- naive adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s).	1
Alectinib Monotherapy. NCCP National SACT Regimen. HSE.	Treatment of adult patients with anaplastic lymphoma kinase (ALK)- positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.	1
Alectinib Monotherapy. NCCP National SACT Regimen. HSE.	As monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).	1
Asciminib Monotherapy. NCCP National SACT Regimen. HSE.	Treatment of adult patients with Philadelphia chromosome positive chronic myeloid leukaemia (Ph+ CML) in the chronic phase (CP), who have previously been treated with two or more tyrosine kinase inhibitors (TKIs).	1
Bosutinib Monotherapy. NCCP National SACT Regimen. HSE.	Treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+CML) previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotonib and dasatinib are not considered appropriate treatment options.	1
Brigatinib Therapy. NCCP National SACT Regimen. HSE.	For the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.	1
Brigatinib Therapy. NCCP National SACT Regimen. HSE.	Monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.	1
Ceritinib Monotherapy. NCCP National SACT Regimen. HSE.	Treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.	1
Cobimetinib and Vemurafenib Therapy. NCCP National SACT Regimen. HSE.	Cobimetinib and vemurafenib in combination are indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.	2
Crizotinib Monotherapy. NCCP National SACT Regimen. HSE.	Treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).	1
Dabrafenib Monotherapy. NCCP National SACT Regimen. HSE.	Treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.	2
Dacomitinib Monotherapy. NCCP National SACT Regimen. HSE.	Monotherapy, for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations	1
Encorafenib and Binimetinib Therapy. NCCP National SACT Regimen. HSE.	Treatment of adult patients with advanced (unresectable or metastatic) melanoma with a BRAF V600 mutation.	2
Entrectinib Therapy. NCCP National SACT Regimen. HSE.	As monotherapy for the treatment of adult patients with ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors	1
Lorlatinib Therapy. NCCP National SACT Regimen. HSE.	As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), following disease progression on (i) alectinib or ceritinib as the first ALK-targeted treatment or (ii) crizotinib and at least one other ALK-targeted treatment.	1
Lorlatinib Therapy. NCCP National SACT Regimen. HSE.	As monotherapy for the treatment of adult patients with ALK-positive advanced NSCLC previously not treated with an ALK inhibitor.	1
Midostaurin, DAUNOrubicin and Cytarabine Induction Therapy. NCCP National SACT Regimen. HSE.	Midostaurin is indicated in combination with standard DAUNOrubicin and cytarabine induction chemotherapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive.	1
Neratinib Therapy. NCCP National SACT Regimen. HSE.	Extended adjuvant treatment of adults with early-stage hormone receptor-positive, HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.	6
Niraparib and Abiraterone acetate (Akeega) and prednisoLONE Therapy. NCCP National SACT Regimen. HSE.	Niraparib in combination with abiraterone acetate (Akeega) and predniSONE/prednisoLONE for the treatment of adults with metastatic castration resistant prostate cancer (mCRPC) and BRCA1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.	3
Olaparib (Tablet) and Bevacizumab Therapy. NCCP National SACT Regimen. HSE.	Olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.	14
Olaparib (Tablet) Monotherapy. NCCP National SACT Regimen. HSE.	Maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA 1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube cancer, and primary peritoneal carcinoma who are in response (complete or partial) following completion of first-line platinum based chemotherapy	12
Olaparib (Tablet) Monotherapy. NCCP National SACT Regimen. HSE.	Maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer who are in response (complete response or partial) to platinum-based chemotherapy	12
Olaparib (Tablet) Monotherapy. NCCP National SACT Regimen. HSE.	As monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.	4
Osimertinib Monotherapy. NCCP National SACT Regimen. HSE.	Treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).	1
Osimertinib Monotherapy. NCCP National SACT Regimen. HSE.	First-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.	1
Osimertinib Monotherapy. NCCP National SACT Regimen. HSE.	As monotherapy for adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) whose tumour has epidermal growth factor receptor (EGFR) exon 19 deletions (Ex19del) or exon 21 (L858R) substitution mutations.	2
PONATinib Therapy. NCCP National SACT Regimen. HSE.	Treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib, nilotinib and bosutinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.	1
PONATinib Therapy. NCCP National SACT Regimen. HSE.	Treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.	2
Talazoparib Therapy. NCCP National SACT Regimen. HSE.	Talazoparib is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine-based therapy or be considered unsuitable for endocrine-based therapy.	2
Trametinib and Dabrafenib Therapy. NCCP National SACT Regimen. HSE.	Treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.	2
Trametinib and Dabrafenib Therapy. NCCP National SACT Regimen. HSE.	Adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.	2
Vemurafenib Monotherapy. NCCP National SACT Regimen. HSE.	Treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.	2
Venetoclax Monotherapy 2021, version number 3, NCCP National SACT Regimen, NCCP, viewed 18/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/400.pdf. NCCP National SACT Regimen. HSE.	Treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.	3
Venetoclax Monotherapy 2021, version number 3, NCCP National SACT Regimen, NCCP, viewed 18/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/400.pdf. NCCP National SACT Regimen. HSE.	Treatment of CLL in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor	1
Zanubrutinib Therapy. NCCP National SACT Regimen. HSE.	As monotherapy for the treatment of adult patients with chronic lymphocytic leukaemia (CLL), who are treatment naive and have del(17p) and/or TP53-mutated disease.	3
Acalabrutinib (Tablets) Monotherapy. NCCP National SACT Regimen. HSE.	As monotherapy for the treatment of previously untreated CLL in the presence of 17p deletion or TP53 mutation in adult patients unsuitable for chemoimmunotherapy.	3
Ibrutinib Therapy CLL / Waldenstroms Macroglobulinaemia. NCCP National SACT Regimen. HSE.	As a single agent for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.	3
Idelalisib and riTUXimab Therapy. NCCP National SACT Regimen. HSE.	In combination with riTUXimab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.	3
Nivolumab 3mg/kg with Ipilimumab 1mg/kg Therapy. NCCP National SACT Regimen. HSE.	Nivolumab in combination with ipilimumab for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer (MSI-H mCRC) after prior fluoropyrimidine-based combination chemotherapy.	2
Pembrolizumab 200mg Monotherapy. NCCP National SACT Regimen. HSE.	First-line treatment of metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express PD-L1 with a >= 50% tumour proportion score (TPS) with no EGFR mutations or ALK translocations.	2
Pembrolizumab 200mg Monotherapy. NCCP National SACT Regimen. HSE.	As monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin-containing chemotherapy whose tumours express PD-L1 with a combined positive score (CPS) >= 10.	1
Pembrolizumab 200mg Monotherapy. NCCP National SACT Regimen. HSE.	As monotherapy for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD-L1 with a CPS >= 1	1
Pembrolizumab 200mg Monotherapy. NCCP National SACT Regimen. HSE.	As monotherapy for the treatment of recurrent, or metastatic cervical cancer with disease progression on or after chemotherapy in adults whose tumours express PD-L1 with a CPS >= 1	1
Pembrolizumab 200mg Monotherapy. NCCP National SACT Regimen. HSE.	First-line treatment of metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in adults	2
Larotrectinib Monotherapy - Paediatric. NCCP National SACT Regimen. HSE.	For the treatment of paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion, (i) who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and (ii) who have no satisfactory treatment options	3
Larotrectinib Monotherapy - Adult. NCCP National SACT Regimen. HSE.	For the treatment of adult patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion, (i) who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and (ii) who have no satisfactory treatment options	3
Gefitinib Monotherapy. NCCP National SACT Regimen. HSE.	Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK	1
Erlotinib Therapy. NCCP National SACT Regimen. HSE.	First-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating mutations	1
Erlotinib Therapy. NCCP National SACT Regimen. HSE.	Switch maintenance treatment in patients with locally advanced or metastatic NSCLC with EGFR activating mutations and stable disease after first-line chemotherapy	1
Trastuzumab Emtansine (Kadcyla) - 21 days. NCCP National SACT Regimen. HSE.	Treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (i) Received prior therapy for locally advanced or metastatic disease, or (ii) Developed disease recurrence during or within six months of completing adjuvant therapy.	1
Palbociclib Therapy - 28 day. NCCP National SACT Regimen. HSE.	Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor	3
Palbociclib Therapy - 28 day. NCCP National SACT Regimen. HSE.	Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant in women who have received prior endocrine therapy	3
Ribociclib Therapy - 28 day. NCCP National SACT Regimen. HSE.	Treatment of postmenopausal women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer as initial endocrine-based therapy in combination with an aromatase inhibitor.	3
Ribociclib Therapy - 28 day. NCCP National SACT Regimen. HSE.	Treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine based therapy or in women who have received prior endocrine therapy. In pre or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone releasing hormone (LHRH) agonist.	6
Inotuzumab Ozogamicin Monotherapy. NCCP National SACT Regimen. HSE.	Monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI).	2
Blinatumomab Paediatric Therapy. NCCP National SACT Regimen. HSE.	As monotherapy for the treatment of paediatric patients aged 1 year or older with Philadelphia chromosome negative CD19 positive B-cell precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation	1
Brentuximab vedotin, Etoposide, methylPREDNISolone, Cytarabine and CISplatin, (ESHAP) therapy (BRESHAP). NCCP National SACT Regimen. HSE.	Treatment of adult patients with relapsed/refractory CD30+ Hodgkin's lymphoma	1
Pertuzumab and Trastuzumab and Chemotherapy Therapy - 21 day cycle. NCCP National SACT Regimen. HSE.	Pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.	2
Pertuzumab and Trastuzumab and Chemotherapy Therapy - 21 day cycle. NCCP National SACT Regimen. HSE.	Pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of adult patients with HER2-positive breast cancer at high risk of recurrence.	5
Gemtuzumab ozogamicin DAUNOrubicin and cytarabine Therapy (AML induction). NCCP National SACT Regimen. HSE.	Gemtuzumab ozogamicin is indicated for combination therapy with DAUNOrubicin and cytarabine for the treatment of patients age 15 years and above with previously untreated, de novo CD33 positive Acute Myeloid Leukemia (AML), except acute promyelocytic leukaemia	1
Pembrolizumab, PEMEtrexed and CARBOplatin (AUC 5) Therapy. NCCP National SACT Regimen. HSE.	Pembrolizumab is indicated in combination with PEMEtrexed and CARBOplatin for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumors have no EGFR or ALK positive mutations	1
Pembrolizumab, PEMEtrexed and CISplatin Therapy. NCCP National SACT Regimen. HSE.	Pembrolizumab is indicated in combination with PEMEtrexed and CISplatin for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumors have no EGFR or ALK positive mutations	1
Durvalumab Monotherapy 10mg/kg - 14 Day. NCCP National SACT Regimen. HSE.	As monotherapy is indicated for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 >= 1% on tumour cells and whose disease has not progressed following platinum-based chemo-radiation therapy (CRT)	1
Atezolizumab Monotherapy. NCCP National SACT Regimen. HSE.	Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy.	2
Atezolizumab Monotherapy. NCCP National SACT Regimen. HSE.	Treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are considered cisplatin ineligible and whose tumours have a PD-L1 expression >= 5%.	1
Atezolizumab Monotherapy. NCCP National SACT Regimen. HSE.	As monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression >= 50% tumour cells (TC) or >= 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC.	2
Atezolizumab Monotherapy. NCCP National SACT Regimen. HSE.	Adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with non-small cell lung cancer (NSCLC) with a high risk of recurrence whose tumours have PD-L1 expression on >= 50% of tumour cells and who do not have EGFR mutant or ALK-positive mutations.	1
Trastuzumab Emtansine (Kadcyla) Early Breast Cancer Therapy - 21 days. NCCP National SACT Regimen. HSE.	As a single agent, is indicated for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy	1
Pembrolizumab, CARBOplatin (AUC 5) and 5-Fluorouracil Therapy. NCCP National SACT Regimen. HSE.	Pembrolizumab is indicated, in combination with CARBOplatin and 5-Fluorouracil, for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD-L1 with a CPS >= 1.	1
Pembrolizumab, Cisplatin and 5-Fluorouracil Therapy. NCCP National SACT Regimen. HSE.	Pembrolizumab is indicated, in combination with CISplatin and 5-fluorouracil, for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD-L1 with a CPS >= 1.	1
Nivolumab, ipilimumab, CARBOplatin and PACLitaxel Therapy. NCCP National SACT Regimen. HSE.	First-line treatment of metastatic squamous non-small cell lung cancer (NSCLC) in adults whose tumours have no sensitising EGFR mutation or ALK translocation.	1
Nivolumab, ipilimumab, PEMEtrexed and CARBOplatin Therapy. NCCP National SACT Regimen. HSE.	First-line treatment of metastatic non-squamous non-small cell lung cancer (NSCLC) in adults whose tumours have no sensitising EGFR mutation or ALK translocation.	1
Nivolumab, ipilimumab, PEMEtrexed and CISplatin Therapy. NCCP National SACT Regimen. HSE.	First-line treatment of metastatic non-squamous non-small cell lung cancer (NSCLC) in adults whose tumours have no sensitising EGFR mutation or ALK translocation.	1
Atezolizumab and nab-PACLitaxel Therapy. NCCP National SACT Regimen. HSE.	Treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression >= 1% and who have not received prior chemotherapy for metastatic disease	1
Blinatumomab Therapy (ALL with MRD >= 0.1%). NCCP National SACT Regimen. HSE.	As monotherapy for the treatment of adults with Philadelphia chromosome negative CD19 positive B-precursor acute lymphoblastic leukaemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%	1
Blinatumomab for Relapsed Paediatric ALL: Consolidation Therapy. NCCP National SACT Regimen. HSE.	As monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed Philadelphia chromosome negative CD19 positive B-precursor acute lymphoblastic leukaemia (ALL) as part of the consolidation therapy.	1
Pertuzumab and Trastuzumab (Phesgo), PACLitaxel and CARBOplatin Therapy (TRAIN-2). NCCP National SACT Regimen. HSE.	Neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.	1
Brentuximab vedotin Monotherapy. NCCP National SACT Regimen. HSE.	Treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy	1
Brentuximab vedotin Monotherapy. NCCP National SACT Regimen. HSE.	Treatment of adult patients with CD30+ Hodgkins Lymphoma (HL) at increased risk of relapse or progression following an autologous haematopoietic stem cell transplant (ASCT).	1
Brentuximab vedotin Monotherapy. NCCP National SACT Regimen. HSE.	Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT)	1
Brentuximab vedotin Monotherapy. NCCP National SACT Regimen. HSE.	Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL) following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option	1
Brentuximab vedotin and ICE Therapy. NCCP National SACT Regimen. HSE.	Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL)	1
Pembrolizumab 200mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy. NCCP National SACT Regimen. HSE.	Pembrolizumab in combination with platinum and fluoropyrimidine-based chemotherapy, for the first line treatment of patients with locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with CPS >= 10.	2
Nivolumab 480mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy. NCCP National SACT Regimen. HSE.	Nivolumab in combination with fluoropyrimidine and platinum-based combination chemotherapy for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC) with tumour cell programmed death ligand 1 (PD-L1) expression >= 1%.	1
Atezolizumab 1680mg Monotherapy - 28 Day. NCCP National SACT Regimen. HSE.	Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy.	2
Atezolizumab 1680mg Monotherapy - 28 Day. NCCP National SACT Regimen. HSE.	Treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression >= 5%	1
Atezolizumab 1680mg Monotherapy - 28 Day. NCCP National SACT Regimen. HSE.	As monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression >= 50% tumour cells (TC) or >= 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC	2
Atezolizumab 1680mg Monotherapy - 28 Day. NCCP National SACT Regimen. HSE.	Adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with non-small cell lung cancer (NSCLC) with a high risk of recurrence whose tumours have PD-L1 expression on >= 50% of tumour cells and who do not have EGFR mutant or ALK-positive mutations.	1
Pembrolizumab and FOLFOX-6 Modified Therapy. NCCP National SACT Regimen. HSE.	Pembrolizumab in combination with platinum and fluoropyrimidine-based chemotherapy, for the first line treatment of patients with locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with CPS >= 10.	1
Blinatumomab Therapy. NCCP National SACT Regimen. HSE.	Treatment of adult patients with relapsed or refractory B cell precursor (BCP) Philadelphia chromosome negative acute lymphoblastic leukaemia (ALL) who have received no prior salvage treatment for relapsed/refractory (R/R) disease and are considered eligible for transplant (i.e. as a bridge-to-transplant).	1
Pertuzumab/Trastuzumab (Phesgo) and Weekly PACLitaxel Therapy - 21 day cycle. NCCP National SACT Regimen. HSE.	Pertuzumab/trastuzumab (Phesgo) is indicated in combination with PACLitaxel in adult patients with HER2- positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti- HER2 therapy or chemotherapy for their metastatic disease where patients are intolerant of, have had significant toxicity to or are deemed clinically unsuitable for DOCEtaxel	1
Pertuzumab,Trastuzumab and Weekly PACLitaxel Therapy - 21 day cycle. NCCP National SACT Regimen. HSE.	Pertuzumab is indicated in combination with trastuzumab and PACLitaxel in adult patients with HER2- positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti- HER2 therapy or chemotherapy for their metastatic disease where patients are intolerant of, have had significant toxicity to or are deemed clinically unsuitable for DOCEtaxel	1
Pertuzumab/Trastuzumab (Phesgo) and DOCEtaxel Therapy - 21 day cycle. NCCP National SACT Regimen. HSE.	Pertuzumab/ trastuzumab (Phesgo) is indicated in combination with DOCEtaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti- HER2 therapy or chemotherapy for their metastatic disease.	1
Pertuzumab,Trastuzumab and DOCEtaxel Therapy - 21 day cycle. NCCP National SACT Regimen. HSE.	Pertuzumab is indicated in combination with trastuzumab and DOCEtaxel in adult patients with HER2- positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti- HER2 therapy or chemotherapy for their metastatic disease.	1
Pertuzumab/Trastuzumab (Phesgo) and Vinorelbine. NCCP National SACT Regimen. HSE.	Pertuzumab/trastuzumab (Phesgo) and vinorelbine for the treatment of adult patients with HER2- positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti- HER2 therapy or chemotherapy for their metastatic disease where patients are deemed clinically unsuitable for taxane based therapy.	1
Pertuzumab, Trastuzumab, and Vinorelbine. NCCP National SACT Regimen. HSE.	Pertuzumab in combination with trastuzumab and vinorelbine for the treatment of adult patients with HER2- positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti- HER2 therapy or chemotherapy for their metastatic disease where patients are deemed clinically unsuitable for taxane based therapy	1
Pertuzumab/Trastuzumab (Phesgo) Maintenance Therapy. NCCP National SACT Regimen. HSE.	Pertuzumab/ trastuzumab (Phesgo) for the maintenance treatment of adult patients with HER2- positive metastatic or locally recurrent unresectable breast cancer, where this is a continuation of treatment for patients who have completed the chemotherapy component of the treatment.	1
DOCEtaxel, CARBOplatin, Trastuzumab and Pertuzumab (TCHP) Therapy. NCCP National SACT Regimen. HSE.	Neoadjuvant treatment of adult patients with HER2-positive locally advanced, inflammatory or early breast cancer at high risk of recurrence.	1
Nivolumab 360mg and Chemotherapy. NCCP National SACT Regimen. HSE.	Nivolumab in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable NSCLC at high risk of recurrence in adult patients whose tumours have PD-L1 expression >= 1%.	5
Pembrolizumab 200mg, weekly CARBOplatin AUC 1.5 and PACLitaxel 80mg/m 2 followed by DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy. NCCP National SACT Regimen. HSE.	Pembrolizumab in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early stage triple negative breast cancer at high risk of recurrence.	1
Trastuzumab (IV) Monotherapy - 21 days. NCCP National SACT Regimen. HSE.	HER2 positive metastatic breast cancer (MBC).	1
Trastuzumab (IV) Monotherapy - 21 days. NCCP National SACT Regimen. HSE.	HER2 positive early breast cancer (EBC).	1
Trastuzumab (IV) Monotherapy - 7 days. NCCP National SACT Regimen. HSE.	Treatment of patients with HER2 positive metastatic breast cancer (MBC).	1
Bevacizumab 10mg/kg - 14 days. NCCP National SACT Regimen. HSE.	In combination with paclitaxel is indicated for first-line treatment of adult patients with HER2-negative metastatic breast cancer.	1
Bevacizumab 15mg/kg Therapy - 21 days. NCCP National SACT Regimen. HSE.	In combination with PACLitaxel is indicated for first-line treatment of adult patients with HER2-negative metastatic breast cancer.	1
Bevacizumab 15mg/kg Therapy - 21 days. NCCP National SACT Regimen. HSE.	In combination with erlotinib is indicated for the first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous cell lung cancer with Epidermal Growth Factor (EGFR) activating mutations	1
Capecitabine Monotherapy. NCCP National SACT Regimen. HSE.	Adjuvant treatment of stage I to IIIB, triple negative breast cancer (TNBC) in patients with residual invasive disease after neoadjuvant chemotherapy treatment.	1
Lapatinib and Capecitabine Therapy. NCCP National SACT Regimen. HSE.	Treatment of adult patients with breast cancer, whose tumours overexpress HER2 in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which should have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting.	1
Tamoxifen Monotherapy. NCCP National SACT Regimen. HSE.	Adjuvant treatment of oestrogen receptor positive breast cancer in pre- or post-menopausal women.	1
Tamoxifen Monotherapy. NCCP National SACT Regimen. HSE.	Treatment of oestrogen receptor positive advanced breast cancer in pre- or post-menopausal women.	1
Anastrozole Monotherapy. NCCP National SACT Regimen. HSE.	Treatment of hormone receptor positive locally advanced or metastatic breast cancer in post-menopausal women.	3
Anastrozole Monotherapy. NCCP National SACT Regimen. HSE.	Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer.	3
DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 days. NCCP National SACT Regimen. HSE.	Adjuvant treatment HER2 positive early breast cancer	1
Trastuzumab Subcutaneous 21 days - Metastatic Breast Cancer. NCCP National SACT Regimen. HSE.	HER2 positive metastatic breast cancer (MBC) as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments.	1
Trastuzumab Subcutaneous 21 days - Metastatic Breast Cancer. NCCP National SACT Regimen. HSE.	HER2 positive metastatic breast cancer (MBC) in combination with PACLitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable.	1
Trastuzumab Subcutaneous 21 days - Metastatic Breast Cancer. NCCP National SACT Regimen. HSE.	HER2 positive metastatic breast cancer (MBC) in combination with DOCEtaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease.	1
Trastuzumab Subcutaneous 21 days - Metastatic Breast Cancer. NCCP National SACT Regimen. HSE.	HER2 positive metastatic breast cancer (MBC) in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab.	3
Trastuzumab Subcutaneous 21 days - Early Breast Cancer. NCCP National SACT Regimen. HSE.	HER2 positive early breast cancer (EBC) following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable).	1
Trastuzumab Subcutaneous 21 days - Early Breast Cancer. NCCP National SACT Regimen. HSE.	HER2 positive early breast cancer (EBC) following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with PACLitaxel or DOCEtaxel.	2
Trastuzumab Subcutaneous 21 days - Early Breast Cancer. NCCP National SACT Regimen. HSE.	HER2 positive early breast cancer (EBC) in combination with adjuvant chemotherapy consisting of DOCEtaxel and CARBOplatin.	1
Trastuzumab Subcutaneous 21 days - Early Breast Cancer. NCCP National SACT Regimen. HSE.	HER2 positive early breast cancer (EBC) in combination with neoadjuvant chemotherapy followed by adjuvant trastuzumab therapy, for locally advanced (including inflammatory) disease or tumours >2cm in diameter.	1
Everolimus and Exemestane Therapy. NCCP National SACT Regimen. HSE.	Treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.	3
CARBOplatin (AUC 6) and Weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin cycloPHOSphamide Therapy-Triple Negative Breast Cancer Therapy. NCCP National SACT Regimen. HSE.	Neoadjuvant treatment of triple negative breast carcinoma.	1
Fulvestrant Therapy. NCCP National SACT Regimen. HSE.	Treatment of postmenopausal women with oestrogen receptor positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant anti-oestrogen therapy.	1
Fulvestrant Therapy. NCCP National SACT Regimen. HSE.	Treatment of postmenopausal women with oestrogen receptor positive, locally advanced or metastatic breast cancer for disease progression on or after adjuvant anti-oestrogen therapy.	1
Letrozole Monotherapy. NCCP National SACT Regimen. HSE.	Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer.	3
Letrozole Monotherapy. NCCP National SACT Regimen. HSE.	Neo-adjuvant treatment of postmenopausal women with hormone receptor positive breast cancer.	3
Exemestane Monotherapy. NCCP National SACT Regimen. HSE.	Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer	3
Gemcitabine and CARBOplatin (AUC2) Therapy - 21 days. NCCP National SACT Regimen. HSE.	Treatment of locally recurrent metastatic triple negative breast cancer.	1
DOXOrubicin, cycloPHOSphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH). NCCP National SACT Regimen. HSE.	Adjuvant Treatment of HER2 positive, High Risk Node Negative or Node Positive Breast Cancer.	1
DOXOrubicin, cycloPHOSphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH). NCCP National SACT Regimen. HSE.	Neoadjuvant Treatment of HER2 positive, High Risk Node Negative or Node Positive Breast Cancer.	1
PACLitaxel (80) and Trastuzumab Therapy - 7 day (12 weeks). NCCP National SACT Regimen. HSE.	Adjuvant Treatment of HER2 positive, Node-Negative Breast Cancer of tumour size <= 3cm.	1
Abemaciclib Therapy. NCCP National SACT Regimen. HSE.	Abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.	12
Pertuzumab and Trastuzumab Therapy. NCCP National SACT Regimen. HSE.	Pertuzumab in combination with trastuzumab for the maintenance treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, where this is a continuation of treatment for patients who have completed the chemotherapy component of the treatment.	1
DOCEtaxel, CARBOplatin, Trastuzumab (S/C) and Pertuzumab (TCH(S/C)P) Therapy. NCCP National SACT Regimen. HSE.	Neoadjuvant treatment of adult patients with HER2-positive locally advanced, inflammatory or early breast cancer at high risk of recurrence.	1
CARBOplatin (AUC 2) weekly and PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin cycloPHOSphamide Therapy - Triple Negative Breast Cancer Therapy. NCCP National SACT Regimen. HSE.	Neoadjuvant treatment of triple negative breast carcinoma	1
Pertuzumab, Trastuzumab, PACLitaxel and CARBOplatin Therapy (TRAIN-2). NCCP National SACT Regimen. HSE.	Neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.	1
DOCEtaxel, CARBOplatin and Pertuzumab/Trastuzumab (Phesgo)(TCHP) Therapy. NCCP National SACT Regimen. HSE.	Neoadjuvant treatment of adult patients with HER2-positive locally advanced, inflammatory or early breast cancer at high risk of recurrence.	1
Pembrolizumab 200mg, CARBOplatin AUC 5 and weekly PACLitaxel 80mg/m 2 followed by DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy. NCCP National SACT Regimen. HSE.	Pembrolizumab in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early stage triple negative breast cancer at high risk of recurrence.	1
Dose Dense DOXOrubicin, cycloPHOSphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (DD AC-TH). NCCP National SACT Regimen. HSE.	Adjuvant Treatment of HER2 positive, High Risk Node Negative or Node Positive Breast Cancer.	1
Dose Dense DOXOrubicin, cycloPHOSphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (DD AC-TH). NCCP National SACT Regimen. HSE.	Neoadjuvant Treatment of HER2 positive, High Risk Node Negative or Node Positive Breast Cancer.	1
Cetuximab Therapy-7 day. NCCP National SACT Regimen. HSE.	As monotherapy for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing RAS wild-type metastatic colorectal cancer (mCRC) in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.	1
Panitumumab 6mg/kg Therapy. NCCP National SACT Regimen. HSE.	Treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC) as monotherapy after failure of fluoropyrimidine, oxaliplatin, and irinotecan containing chemotherapy regimens.	1
Cetuximab (7 days) and FOLFIRI (14 days) Therapy. NCCP National SACT Regimen. HSE.	Treatment of patients with RAS wild type metastatic colorectal cancer.	1
Cetuximab (7 days) and Irinotecan (14 days) Therapy. NCCP National SACT Regimen. HSE.	Second line therapy for metastatic colorectal cancer with non-mutated (wild type) RAS after failure of or contraindication to oxaliplatin based therapy.	1
Cetuximab (14 days) and Irinotecan (14 days) Therapy. NCCP National SACT Regimen. HSE.	Second line therapy for metastatic colorectal cancer with non-mutated (wild type) RAS after failure of or contraindication to oxaliplatin based therapy.	1
Panitumumab 6mg/kg and Modified FOLFOX-6 Therapy - 14 day. NCCP National SACT Regimen. HSE.	First line treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC).	1
Panitumumab 6mg/kg and FOLFIRI Therapy-14 day. NCCP National SACT Regimen. HSE.	First line treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC).	1
Panitumumab 6mg/kg and FOLFIRI Therapy-14 day. NCCP National SACT Regimen. HSE.	Second line treatment of adult patients with wild-type RAS mCRC who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan).	1
Trastuzumab 5-Fluorouracil and CISplatin Therapy - 21 days. NCCP National SACT Regimen. HSE.	Treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.	1
Cetuximab (14 days) and FOLFIRI (14 days) Therapy. NCCP National SACT Regimen. HSE.	Treatment of patients with RAS wild type metastatic colorectal cancer.	1
Nivolumab 240mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy. NCCP National SACT Regimen. HSE.	Nivolumab in combination with fluoropyrimidine and platinum-based combination chemotherapy for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC) with tumour cell programmed death ligand 1 (PD-L1) expression >= 1%.	1
Nivolumab and FOLFOX-6 Modified Therapy. NCCP National SACT Regimen. HSE.	Nivolumab in combination with fluoropyrimidine and platinum-based combination chemotherapy for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC) with tumour cell programmed death ligand 1 (PD-L1) expression >= 1%.	1
Pembrolizumab 400mg Monotherapy. NCCP National SACT Regimen. HSE.	First-line treatment of metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express PD-L1 with a >= 50% tumour proportion score (TPS) with no EGFR mutations or ALK translocations.	1
Pembrolizumab 400mg Monotherapy. NCCP National SACT Regimen. HSE.	As monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin-containing chemotherapy whose tumours express PD-L1 with a combined positive score (CPS) >= 10.	1
Pembrolizumab 400mg Monotherapy. NCCP National SACT Regimen. HSE.	As monotherapy for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD-L1 with a CPS >= 1	1
Pembrolizumab 400mg Monotherapy. NCCP National SACT Regimen. HSE.	As monotherapy for the treatment of recurrent, or metastatic cervical cancer with disease progression on or after chemotherapy in adults whose tumours express PD-L1 with a CPS >= 1	1
Pembrolizumab 400mg Monotherapy. NCCP National SACT Regimen. HSE.	First-line treatment of metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in adults	1
Pembrolizumab, PACLitaxel 175mg/m2, CARBOplatin AUC 5 and Bevacizumab Therapy. NCCP National SACT Regimen. HSE.	Treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD-L1 with a CPS >= 1.	1
Pembrolizumab, PACLitaxel 175mg/m2 and CARBOplatin AUC 5 Therapy. NCCP National SACT Regimen. HSE.	Treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD-L1 with a CPS >= 1.	1
Idelalisib and Ofatumumab Therapy. NCCP National SACT Regimen. HSE.	In combination with Ofatumumab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.	3
Midostaurin Maintenance Therapy. NCCP National SACT Regimen. HSE.	Midostaurin is indicated as single agent maintenance therapy for adult patients with FLT3 mutation positive acute myeloid leukaemia (AML) in complete response after completion of induction and consolidation chemotherapy.	1
Midostaurin and Intermediate Dose Cytarabine Consolidation Therapy. NCCP National SACT Regimen. HSE.	Midostaurin is indicated in combination with intermediate dose cytarabine consolidation chemotherapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive	1
Gemcitabine (1250mg/m2) and CISplatin (75mg/m2) Therapy - 21 day. NCCP National SACT Regimen. HSE.	In combination with nivolumab for the neoadjuvant treatment of resectable NSCLC at high risk of recurrence in adult patients whose tumours have PD-L1 expression >= 1% (3 cycles only). This combination is available in NCIS (00849.3)	1
CARBOplatin (AUC 6) and PACLitaxel 200mg/m2 Therapy. NCCP National SACT Regimen. HSE.	In combination with nivolumab for the neoadjuvant treatment of resectable NSCLC at high risk of recurrence in adult patients whose tumours have PD-L1 expression >= 1% (3 cycles only). This combination is available in NCIS (00849.1)	1
Gemcitabine (1000mg/m2) and CARBOplatin (AUC 5) Therapy - 21 day. NCCP National SACT Regimen. HSE.	In combination with nivolumab for the neoadjuvant treatment of resectable NSCLC at high risk of recurrence in adult patients whose tumours have PD-L1 expression >= 1% (3 cycles only). This combination is available in NCIS (00849.2)	1
PEMEtrexed and CISplatin Therapy. NCCP National SACT Regimen. HSE.	In combination with nivolumab for the neoadjuvant treatment of resectable NSCLC at high risk of recurrence in adult patients whose tumours have PD-L1 expression >= 1% (3 cycles only). This combination is available in NCIS (00849.5)	1
PEMEtrexed and CARBOplatin Therapy. NCCP National SACT Regimen. HSE.	In combination with nivolumab for the neoadjuvant treatment of resectable NSCLC at high risk of recurrence in adult patients whose tumours have PD-L1 expression >= 1% (3 cycles only). This combination is available in NCIS (00849.4)	1
Atezolizumab 840mg Monotherapy - 14 Day. NCCP National SACT Regimen. HSE.	Treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are considered cisplatin ineligible and whose tumours have a PD-L1 expression >= 5%.	1
Atezolizumab 840mg Monotherapy - 14 Day. NCCP National SACT Regimen. HSE.	As monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PDL1 expression >= 50% tumour cells (TC) or >= 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC.	2
Atezolizumab 840mg Monotherapy - 14 Day. NCCP National SACT Regimen. HSE.	Adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with non-small cell lung cancer (NSCLC) with a high risk of recurrence whose tumours have PD-L1 expression on >= 50% of tumour cells and who do not have EGFR mutant or ALK-positive mutations.	1
Durvalumab Monotherapy 1500 mg - 28 day. NCCP National SACT Regimen. HSE.	As monotherapy is indicated for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 >= 1% on tumour cells and whose disease has not progressed following platinum-based chemo-radiation therapy (CRT).	1
(*riTUXimab) cycloPHOSphamide, DOXOrubicin, vinCRIStine and prednisoLONE (*R)-CHOP) Therapy - 21 days. NCCP National SACT Regimen. HSE.	Treatment of Non Hodgkins Lymphoma (NHL). Rituximab to be included in CD20 positive patients.	1
RiTUXimab and Bendamustine Therapy. NCCP National SACT Regimen. HSE.	Treatment of patients with previously untreated indolent CD20-positive, stage III-IV non-hodgkin lymphoma (NHL).	1
RiTUXimab and Bendamustine Therapy. NCCP National SACT Regimen. HSE.	Treatment of patients with previously untreated CD20-positive, stage III-IV mantle cell lymphoma (MCL), ineligible for autologous stem cell transplant.	1
(R*)-DHAP Therapy. NCCP National SACT Regimen. HSE.	Treatment of relapsed Non Hodgkin Lymphoma. Rituximab to be included in CD20 positive patients.	1
Dose Adjusted riTUXimab, Etoposide, prednisoLONE, DOXOrubicin, cycloPHOSphamide and vinCRIStine (DA-R EPOCH) Therapy. NCCP National SACT Regimen. HSE.	Treatment of patients with CD20 positive diffuse large B-cell Non Hodgkins lymphoma (NHL).	2
(R*)-ICE ((riTUXimab), Ifosfamide, CARBOplatin and Etoposide) Therapy. NCCP National SACT Regimen. HSE.	Treatment of relapsed / refractory Non Hodgkin's Lymphoma. Rituximab to be included in CD20 positive patients.	1
(*riTUXimab) cycloPHOSphamide, DOXOrubicin, vinCRIStine and prednisoLONE (*R)-CHOP Therapy - 14 day. NCCP National SACT Regimen. HSE.	Treatment of Non Hodgkin's Lymphoma (NHL). Rituximab to be included in CD20 positive patients.	1
(R*)- miniCHOP Therapy - 21 days. NCCP National SACT Regimen. HSE.	Treatment of Non Hodgkin Lymphoma in patients aged greater than 80 or with significant co-morbidities. Rituximab to be included in all CD20 positive patients.	1
R-Gemcitabine (1000mg/m2) Oxaliplatin Therapy - 14 day. NCCP National SACT Regimen. HSE.	Relapsed or refractory CD20 positive diffuse large B cell lymphoma in patients ineligible for stem cell transplant.	2
R-CEOP Therapy - 21 days. NCCP National SACT Regimen. HSE.	Treatment of Non Hodgkin CD20 positive Lymphoma for patients not suitable for anthracycline therapy.	1
Brentuximab vedotin and Bendamustine Therapy. NCCP National SACT Regimen. HSE.	Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL).	1
riTUXimab 375 mg/m2 Combination Therapy-21 day. NCCP National SACT Regimen. HSE.	In combination with chemotherapy for induction treatment of previously untreated or relapsed/ refractory CD 20 positive patients with follicular lymphoma.	4
RiTUXimab 375 mg/m2 Maintenance Therapy- 56 day. NCCP National SACT Regimen. HSE.	Maintenance therapy for the treatment of previously untreated follicular CD20 positive, B-cell Non Hodgkin Lymphoma patients responding to induction therapy.	2
riTUXimab (S/C 1400mg) Maintenance Therapy-84 day. NCCP National SACT Regimen. HSE.	Maintenance therapy for the treatment of relapsed/refractory follicular CD20 positive, B-cell Non Hodgkin Lymphoma (NHL) in patients who have responded to induction therapy.	2
riTUXimab (S/C 1400mg) Maintenance Therapy-56 day. NCCP National SACT Regimen. HSE.	Maintenance therapy for the treatment of previously untreated follicular CD20 positive, B-cell Non Hodgkin Lymphoma patients responding to induction therapy.	2
Dose Adjusted riTUXimab S/C, Etoposide, prednisoLONE, DOXOrubicin, cycloPHOSphamide and vinCRIStine. NCCP National SACT Regimen. HSE.	Treatment of patients with CD20 positive diffuse large B-cell Non Hodgkin's lymphoma (NHL).	2
riTUXimab, Cyclophosphamide, vinCRIStine and prednisoLONE R-CVP Therapy-21 days. NCCP National SACT Regimen. HSE.	First line treatment of patients with low grade B cell Non Hodgkin's lymphoma (NHL). Rituximab to be included in CD20 positive patients.	1
riTUXimab, Cyclophosphamide, vinCRIStine and prednisoLONE R-CVP Therapy-21 days. NCCP National SACT Regimen. HSE.	Treatment of patients with relapsed/refractory low grade B cell Non Hodgkin's lymphoma (NHL).	1
RiTUXimab 375 mg/m2 Maintenance Therapy-84 day. NCCP National SACT Regimen. HSE.	Maintenance therapy for the treatment of relapsed/refractory follicular CD20 positive, B-cell Non Hodgkin Lymphoma (NHL) in patients who have responded to induction therapy.	2
Imatinib Therapy - GIST. NCCP National SACT Regimen. HSE.	Treatment of adult patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).	1
Imatinib Therapy - GIST. NCCP National SACT Regimen. HSE.	Adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST.	1
Tepotinib Therapy. NCCP National SACT Regimen. HSE.	As monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.	2
Trastuzumab Deruxtecan (Enhertu) Therapy. NCCP National SACT Regimen. HSE.	As monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.	1
Pembrolizumab 400mg, CARBOplatin AUC 5 and weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy. NCCP National SACT Regimen. HSE.	Pembrolizumab in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early stage triple negative breast cancer at high risk of recurrence.	1
Pembrolizumab 400mg, Weekly CARBOplatin AUC 1.5 and PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy. NCCP National SACT Regimen. HSE.	Pembrolizumab in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early stage triple negative breast cancer at high risk of recurrence.	1
Vandetanib Therapy. NCCP National SACT Regimen. HSE.	Treatment of medullary thyroid cancer (MTC) in patients with Rearranged during Transfection (RET) mutation positive, unresectable locally advanced or metastatic disease.	1
Trentinoin (ATRA) and Arsenic Trioxide (ATO) Induction Therapy. NCCP National SACT Regimen. HSE.	Treatement of patients with newly diagnosed low to intermediate risk Acute Promyelocytic Leukaemia (APL) (defined as WCC count <= 10x10^9/L)	1
Trentinoin (ATRA) and Arsenic Trioxide (ATO) Induction Therapy. NCCP National SACT Regimen. HSE.	Treatement of patients with relapsed or refractory APL after ATRA/chemotherapy	1
Sacituzumab Govitecan Therapy. NCCP National SACT Regimen. HSE.	As monotherapy for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, including at least one of them for advanced disease.	1
Entrectinib Monotherapy - Adult. NCCP National SACT Regimen. HSE.	For the treatment of adult patients with solid tumors expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who: (i) have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and (ii) who have not received a prior NTRK inhibitor, and (iii) who have no satisfactory treatment options.	3
Anastrozole Monotherapy. NCCP National SACT Regimen. HSE.	Extended adjuvant treatment of hormone-dependent-invasive breast cancer in postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.	3
Letrozole Monotherapy. NCCP National SACT Regimen. HSE.	Extended adjuvant treatment of hormone-dependent-invasive breast cancer in postmenopausal women who have received prior adjuvant endocrine therapy for 5 years.	3
Letrozole Monotherapy. NCCP National SACT Regimen. HSE.	Advanced breast cancer after relapse or disease progression, in women with natural or artificially induced postmenopausal endocrine status.	3

Therapeutic response

Precision oncology relationships for therapeutic response derived from Health Service Executive's regulatory approvals.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	EGFR oncogenic variants	Non-Small Cell Lung Cancer	Afatinib
Sensitivity (+)	v::ALK	Non-Small Cell Lung Cancer	Alectinib
Sensitivity (+)	v::ALK	Non-Small Cell Lung Cancer	Alectinib
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Asciminib
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Bosutinib
Sensitivity (+)	v::ALK	Non-Small Cell Lung Cancer	Brigatinib
Sensitivity (+)	v::ALK	Non-Small Cell Lung Cancer	Brigatinib
Sensitivity (+)	v::ALK	Non-Small Cell Lung Cancer	Ceritinib
Sensitivity (+)	BRAF p.V600E	Melanoma	Cobimetinib, Vemurafenib
Sensitivity (+)	BRAF p.V600K	Melanoma	Cobimetinib, Vemurafenib
Sensitivity (+)	v::ALK	Non-Small Cell Lung Cancer	Crizotinib
Sensitivity (+)	BRAF p.V600E	Melanoma	Dabrafenib
Sensitivity (+)	BRAF p.V600K	Melanoma	Dabrafenib
Sensitivity (+)	EGFR oncogenic variants	Non-Small Cell Lung Cancer	Dacomitinib
Sensitivity (+)	BRAF p.V600E	Melanoma	Binimetinib, Encorafenib
Sensitivity (+)	BRAF p.V600K	Melanoma	Binimetinib, Encorafenib
Sensitivity (+)	v::ROS1	Non-Small Cell Lung Cancer	Entrectinib
Sensitivity (+)	v::ALK	Non-Small Cell Lung Cancer	Lorlatinib
Sensitivity (+)	v::ALK	Non-Small Cell Lung Cancer	Lorlatinib
Sensitivity (+)	FLT3-ITD	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin
Sensitivity (+)	ER positive, HER2-positive, PR positive	Invasive Breast Carcinoma	Neratinib
Sensitivity (+)	ER positive, HER2-positive	Invasive Breast Carcinoma	Neratinib
Sensitivity (+)	HER2-positive, PR positive	Invasive Breast Carcinoma	Neratinib
Sensitivity (+)	ER positive, ERBB2 amplification, PR positive	Invasive Breast Carcinoma	Neratinib
Sensitivity (+)	ER positive, ERBB2 amplification	Invasive Breast Carcinoma	Neratinib
Sensitivity (+)	ERBB2 amplification, PR positive	Invasive Breast Carcinoma	Neratinib
Sensitivity (+)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisolone
Sensitivity (+)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisolone
Sensitivity (+)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisolone
Sensitivity (+)	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
Sensitivity (+)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
Sensitivity (+)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
Sensitivity (+)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
Sensitivity (+)	BRCA1 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib
Sensitivity (+)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib
Sensitivity (+)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib
Sensitivity (+)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib
Sensitivity (+)	BRCA1 oncogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib
Sensitivity (+)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib
Sensitivity (+)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib
Sensitivity (+)	HRD	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
Sensitivity (+)	HRD	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib
Sensitivity (+)	HRD	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib
Sensitivity (+)	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Olaparib
Sensitivity (+)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Olaparib
Sensitivity (+)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Olaparib
Sensitivity (+)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Olaparib
Sensitivity (+)	BRCA1 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
Sensitivity (+)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
Sensitivity (+)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
Sensitivity (+)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
Sensitivity (+)	BRCA1 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib
Sensitivity (+)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib
Sensitivity (+)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib
Sensitivity (+)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib
Sensitivity (+)	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Olaparib
Sensitivity (+)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Olaparib
Sensitivity (+)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Olaparib
Sensitivity (+)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Olaparib
Sensitivity (+)	BRCA1 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
Sensitivity (+)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
Sensitivity (+)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
Sensitivity (+)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
Sensitivity (+)	BRCA1 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib
Sensitivity (+)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib
Sensitivity (+)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib
Sensitivity (+)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib
Sensitivity (+)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Olaparib
Sensitivity (+)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Olaparib
Sensitivity (+)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Olaparib
Sensitivity (+)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Olaparib
Sensitivity (+)	EGFR p.T790M	Non-Small Cell Lung Cancer	Osimertinib
Sensitivity (+)	EGFR oncogenic variants	Non-Small Cell Lung Cancer	Osimertinib
Sensitivity (+)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Osimertinib
Sensitivity (+)	EGFR p.L858R	Non-Small Cell Lung Cancer	Osimertinib
Sensitivity (+)	ABL1 p.T315I	Chronic Myelogenous Leukemia	Ponatinib
Sensitivity (+)	BCR::ABL1	Acute Lymphoid Leukemia	Ponatinib
Sensitivity (+)	ABL1 p.T315I, BCR::ABL1	Acute Lymphoid Leukemia	Ponatinib
Sensitivity (+)	BRCA1 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Talazoparib
Sensitivity (+)	BRCA2 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Talazoparib
Sensitivity (+)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Melanoma	Vemurafenib
Sensitivity (+)	BRAF p.V600K	Melanoma	Vemurafenib
Sensitivity (+)	TP53 somatic variants	Chronic Lymphocytic Leukemia	Venetoclax
Sensitivity (+)	TP53 deletion	Chronic Lymphocytic Leukemia	Venetoclax
Sensitivity (+)	17p deletion	Chronic Lymphocytic Leukemia	Venetoclax
Sensitivity (+)	Wild type TP53	Chronic Lymphocytic Leukemia	Venetoclax
Sensitivity (+)	TP53 somatic variants	Chronic Lymphocytic Leukemia	Zanubrutinib
Sensitivity (+)	TP53 deletion	Chronic Lymphocytic Leukemia	Zanubrutinib
Sensitivity (+)	17p deletion	Chronic Lymphocytic Leukemia	Zanubrutinib
Sensitivity (+)	TP53 somatic variants	Chronic Lymphocytic Leukemia	Acalabrutinib
Sensitivity (+)	TP53 deletion	Chronic Lymphocytic Leukemia	Acalabrutinib
Sensitivity (+)	17p deletion	Chronic Lymphocytic Leukemia	Acalabrutinib
Sensitivity (+)	TP53 somatic variants	Chronic Lymphocytic Leukemia	Ibrutinib
Sensitivity (+)	TP53 deletion	Chronic Lymphocytic Leukemia	Ibrutinib
Sensitivity (+)	17p deletion	Chronic Lymphocytic Leukemia	Ibrutinib
Sensitivity (+)	TP53 deletion	Chronic Lymphocytic Leukemia	Idelalisib, Rituximab
Sensitivity (+)	TP53 somatic variants	Chronic Lymphocytic Leukemia	Idelalisib, Rituximab
Sensitivity (+)	17p deletion	Chronic Lymphocytic Leukemia	Idelalisib, Rituximab
Sensitivity (+)	MSI-H	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab
Sensitivity (+)	dMMR	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab
Sensitivity (+)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Pembrolizumab
Sensitivity (+)	CD274 amplification, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Pembrolizumab
Sensitivity (+)	PD-L1 (CPS) >= 10	Bladder Urothelial Carcinoma	Pembrolizumab
Sensitivity (+)	PD-L1 (CPS) >= 1	Head and Neck Squamous Cell Carcinoma	Pembrolizumab
Sensitivity (+)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Pembrolizumab
Sensitivity (+)	dMMR	Colorectal Adenocarcinoma	Pembrolizumab
Sensitivity (+)	MSI-H	Colorectal Adenocarcinoma	Pembrolizumab
Sensitivity (+)	v::NTRK1	Any solid tumor	Larotrectinib
Sensitivity (+)	v::NTRK2	Any solid tumor	Larotrectinib
Sensitivity (+)	v::NTRK3	Any solid tumor	Larotrectinib
Sensitivity (+)	v::NTRK1	Any solid tumor	Larotrectinib
Sensitivity (+)	v::NTRK2	Any solid tumor	Larotrectinib
Sensitivity (+)	v::NTRK3	Any solid tumor	Larotrectinib
Sensitivity (+)	EGFR oncogenic variants	Non-Small Cell Lung Cancer	Gefitinib
Sensitivity (+)	EGFR oncogenic variants	Non-Small Cell Lung Cancer	Erlotinib
Sensitivity (+)	EGFR oncogenic variants	Non-Small Cell Lung Cancer	Erlotinib
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab emtansine
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Palbociclib
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Letrozole, Palbociclib
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Palbociclib
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Palbociclib
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Fulvestrant, Palbociclib
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Palbociclib
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Ribociclib
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Letrozole, Ribociclib
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Ribociclib
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Ribociclib
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Ribociclib
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Letrozole, Ribociclib
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Ribociclib
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Fulvestrant, Ribociclib
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Ribociclib
Sensitivity (+)	CD22 +	Acute Lymphoid Leukemia	Inotuzumab ozogamicin
Sensitivity (+)	BCR::ABL1, CD22 +	Acute Lymphoid Leukemia	Inotuzumab ozogamicin
Sensitivity (+)	BCR::ABL1, CD19 +	Acute Lymphoid Leukemia	Blinatumomab
Sensitivity (+)	CD30 +	Hodgkin Lymphoma	Brentuximab Vedotin, Cisplatin, Cytarabine, Etoposide
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Pertuzumab, Trastuzumab
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Pertuzumab, Trastuzumab
Sensitivity (+)	CD33 +	Acute Lymphoid Leukemia	Cytarabine, Daunorubicin, Gemtuzumab ozogamicin
Sensitivity (+)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Pembrolizumab, Pemetrexed
Sensitivity (+)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Pembrolizumab, Pemetrexed
Sensitivity (+)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Durvalumab
Sensitivity (+)	EGFR somatic variants	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (+)	v::ALK	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (+)	PD-L1 >= 5%	Bladder Urothelial Carcinoma	Atezolizumab
Sensitivity (+)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (+)	PD-L1 >= 10% TIIC, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (+)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab emtansine
Sensitivity (+)	PD-L1 (CPS) >= 1	Head and Neck Squamous Cell Carcinoma	Carboplatin, Fluorouracil, Pembrolizumab
Sensitivity (+)	PD-L1 (CPS) >= 1	Head and Neck Squamous Cell Carcinoma	Cisplatin, Fluorouracil, Pembrolizumab
Sensitivity (+)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
Sensitivity (+)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Ipilimumab, Nivolumab, Pemetrexed
Sensitivity (+)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Ipilimumab, Nivolumab, Pemetrexed
Sensitivity (+)	ER negative, HER2-negative, PD-L1 >= 1%, PR negative	Invasive Breast Carcinoma	Atezolizumab, Nab-paclitaxel
Sensitivity (+)	BCR::ABL1, CD19 +	Acute Lymphoid Leukemia	Blinatumomab
Sensitivity (+)	BCR::ABL1, CD19 +	Acute Lymphoid Leukemia	Blinatumomab
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Paclitaxel, Pertuzumab, Trastuzumab
Sensitivity (+)	CD30 +	Cutaneous T-cell Lymphoma	Brentuximab Vedotin
Sensitivity (+)	CD30 +	Hodgkin Lymphoma	Brentuximab Vedotin
Sensitivity (+)	CD30 +	Hodgkin Lymphoma	Brentuximab Vedotin
Sensitivity (+)	CD30 +	Hodgkin Lymphoma	Brentuximab Vedotin
Sensitivity (+)	CD30 +, HER2-negative	Hodgkin Lymphoma	Brentuximab Vedotin, Carboplatin, Etoposide, Ifosfamide
Sensitivity (+)	PD-L1 (CPS) >= 10	Esophageal Adenocarcinoma	Cisplatin, Fluorouracil, Pembrolizumab
Sensitivity (+)	HER2-negative, PD-L1 (CPS) >= 10	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Pembrolizumab
Sensitivity (+)	PD-L1 >= 1%	Esophageal Squamous Cell Carcinoma	Cisplatin, Fluorouracil, Nivolumab
Sensitivity (+)	EGFR somatic variants	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (+)	v::ALK	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (+)	PD-L1 >= 5%	Bladder Urothelial Carcinoma	Atezolizumab
Sensitivity (+)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (+)	PD-L1 >= 10% TIIC, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (+)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (+)	HER2-negative, PD-L1 (CPS) >= 10	Adenocarcinoma of the Gastroesophageal Junction	Fluorouracil, Oxaliplatin, Pembrolizumab
Sensitivity (+)	BCR::ABL1	Acute Lymphoid Leukemia	Blinatumomab
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Paclitaxel, Pertuzumab, Trastuzumab
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Paclitaxel, Pertuzumab, Trastuzumab
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Pertuzumab, Trastuzumab
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Pertuzumab, Trastuzumab
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Pertuzumab, Trastuzumab, Vinorelbine
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Pertuzumab, Trastuzumab, Vinorelbine
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Pertuzumab, Trastuzumab
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Pertuzumab, Trastuzumab
Sensitivity (+)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Carboplatin, Nivolumab, Paclitaxel
Sensitivity (+)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Carboplatin, Nivolumab, Pemetrexed
Sensitivity (+)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Cisplatin, Gemcitabine, Nivolumab
Sensitivity (+)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Carboplatin, Gemcitabine, Nivolumab
Sensitivity (+)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Cisplatin, Nivolumab, Pemetrexed
Sensitivity (+)	ER negative, HER2-negative, PR negative	Invasive Breast Carcinoma	Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel, Pembrolizumab
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab
Sensitivity (+)	HER2-negative	Invasive Breast Carcinoma	Bevacizumab, Paclitaxel
Sensitivity (+)	HER2-negative	Invasive Breast Carcinoma	Bevacizumab, Paclitaxel
Sensitivity (+)	EGFR oncogenic variants	Non-Small Cell Lung Cancer	Bevacizumab, Erlotinib
Sensitivity (+)	ER negative, HER2-negative, PR negative	Invasive Breast Carcinoma	Capecitabine
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Capecitabine, Lapatinib
Sensitivity (+)	ER positive	Invasive Breast Carcinoma	Tamoxifen
Sensitivity (+)	ER positive	Invasive Breast Carcinoma	Tamoxifen
Sensitivity (+)	ER positive, HER2-positive, PR positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (+)	ER positive, HER2-positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (+)	HER2-positive, PR positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (+)	ER positive, HER2-positive, PR positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (+)	ER positive, HER2-positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (+)	HER2-positive, PR positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Trastuzumab
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Paclitaxel, Trastuzumab
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Trastuzumab
Sensitivity (+)	ER positive, HER2-positive, PR positive	Invasive Breast Carcinoma	Anastrozole, Trastuzumab
Sensitivity (+)	ER positive, HER2-positive	Invasive Breast Carcinoma	Anastrozole, Trastuzumab
Sensitivity (+)	HER2-positive, PR positive	Invasive Breast Carcinoma	Anastrozole, Trastuzumab
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Trastuzumab
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Paclitaxel, Trastuzumab
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Trastuzumab
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Doxorubicin, Paclitaxel, Trastuzumab
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Everolimus, Exemestane
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Everolimus, Exemestane
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Everolimus, Exemestane
Sensitivity (+)	ER negative, HER2-negative, PR negative	Invasive Breast Carcinoma	Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel
Sensitivity (+)	ER negative	Invasive Breast Carcinoma	Fulvestrant
Sensitivity (+)	ER negative	Invasive Breast Carcinoma	Fulvestrant
Sensitivity (+)	ER positive, PR positive	Invasive Breast Carcinoma	Letrozole
Sensitivity (+)	ER positive	Invasive Breast Carcinoma	Letrozole
Sensitivity (+)	PR positive	Invasive Breast Carcinoma	Letrozole
Sensitivity (+)	ER positive, PR positive	Invasive Breast Carcinoma	Letrozole
Sensitivity (+)	ER positive	Invasive Breast Carcinoma	Letrozole
Sensitivity (+)	PR positive	Invasive Breast Carcinoma	Letrozole
Sensitivity (+)	ER positive, PR positive	Invasive Breast Carcinoma	Exemestane
Sensitivity (+)	ER positive	Invasive Breast Carcinoma	Exemestane
Sensitivity (+)	PR positive	Invasive Breast Carcinoma	Exemestane
Sensitivity (+)	ER negative, HER2-negative, PR negative	Invasive Breast Carcinoma	Carboplatin, Gemcitabine
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Paclitaxel, Trastuzumab
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Paclitaxel, Trastuzumab
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Paclitaxel, Trastuzumab
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Exemestane
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Exemestane
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Exemestane
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Letrozole
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Letrozole
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Letrozole
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Letrozole
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Letrozole
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Letrozole
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Pertuzumab, Trastuzumab
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Pertuzumab, Trastuzumab
Sensitivity (+)	ER negative, HER2-negative, PR negative	Invasive Breast Carcinoma	Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Paclitaxel, Pertuzumab, Trastuzumab
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Pertuzumab, Trastuzumab
Sensitivity (+)	ER negative, HER2-negative, PR negative	Invasive Breast Carcinoma	Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel, Pembrolizumab
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Paclitaxel, Trastuzumab
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Paclitaxel, Trastuzumab
Sensitivity (+)	EGFR positive, Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Cetuximab
Sensitivity (+)	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Panitumumab
Sensitivity (+)	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Cetuximab, Fluorouracil, Irinotecan
Sensitivity (+)	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Cetuximab, Irinotecan
Sensitivity (+)	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Cetuximab, Irinotecan
Sensitivity (+)	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Fluorouracil, Oxaliplatin, Panitumumab
Sensitivity (+)	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Fluorouracil, Irinotecan, Panitumumab
Sensitivity (+)	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Fluorouracil, Irinotecan, Panitumumab
Sensitivity (+)	HER2-positive	Esophagogastric Adenocarcinoma	Cisplatin, Fluorouracil, Trastuzumab
Sensitivity (+)	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Cetuximab, Fluorouracil, Irinotecan
Sensitivity (+)	PD-L1 >= 1%	Esophageal Squamous Cell Carcinoma	Cisplatin, Fluorouracil, Nivolumab
Sensitivity (+)	PD-L1 >= 1%	Esophageal Squamous Cell Carcinoma	Fluorouracil, Nivolumab, Oxaliplatin
Sensitivity (+)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Pembrolizumab
Sensitivity (+)	PD-L1 (CPS) >= 10	Bladder Urothelial Carcinoma	Pembrolizumab
Sensitivity (+)	PD-L1 (CPS) >= 1	Head and Neck Squamous Cell Carcinoma	Pembrolizumab
Sensitivity (+)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Pembrolizumab
Sensitivity (+)	MSI-H	Colorectal Adenocarcinoma	Pembrolizumab
Sensitivity (+)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab
Sensitivity (+)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Carboplatin, Paclitaxel, Pembrolizumab
Sensitivity (+)	TP53 somatic variants	Chronic Lymphocytic Leukemia	Idelalisib, Ofatumumab
Sensitivity (+)	TP53 deletion	Chronic Lymphocytic Leukemia	Idelalisib, Ofatumumab
Sensitivity (+)	17p deletion	Chronic Lymphocytic Leukemia	Idelalisib, Ofatumumab
Sensitivity (+)	FLT3-ITD	Acute Myeloid Leukemia	Midostaurin
Sensitivity (+)	FLT3-ITD	Acute Myeloid Leukemia	Midostaurin
Sensitivity (+)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Cisplatin, Gemcitabine, Nivolumab
Sensitivity (+)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Carboplatin, Nivolumab, Paclitaxel
Sensitivity (+)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Carboplatin, Gemcitabine, Nivolumab
Sensitivity (+)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Cisplatin, Nivolumab, Pemetrexed
Sensitivity (+)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Carboplatin, Nivolumab, Pemetrexed
Sensitivity (+)	PD-L1 >= 5%	Bladder Urothelial Carcinoma	Atezolizumab
Sensitivity (+)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (+)	PD-L1 >= 10% TIIC, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (+)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (+)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Durvalumab
Sensitivity (+)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine
Sensitivity (+)	CD20 +	Non-Hodgkin Lymphoma	Bendamustine, Rituximab
Sensitivity (+)	CD20 +	Non-Hodgkin Lymphoma	Bendamustine, Rituximab
Sensitivity (+)	CD20 +	Non-Hodgkin Lymphoma	Cisplatin, Cytarabine, Rituximab
Sensitivity (+)	CD20 +	Diffuse Large B-Cell Lymphoma	Cyclophosphamide, Doxorubicin, Etoposide, Prednisolone, Rituximab, Vincristine
Sensitivity (+)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Doxorubicin, Etoposide, Prednisolone, Rituximab, Vincristine
Sensitivity (+)	CD20 +	Non-Hodgkin Lymphoma	Carboplatin, Etoposide, Ifosfamide, Rituximab
Sensitivity (+)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vinorelbine
Sensitivity (+)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vinorelbine
Sensitivity (+)	CD20 +	Diffuse Large B-Cell Lymphoma	Gemcitabine, Oxaliplatin, Rituximab
Sensitivity (+)	CD20 +	Non-Hodgkin Lymphoma	Gemcitabine, Oxaliplatin, Rituximab
Sensitivity (+)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Etoposide, Prednisolone, Rituximab, Vincristine
Sensitivity (+)	CD30 +	Hodgkin Lymphoma	Bendamustine, Brentuximab Vedotin
Sensitivity (+)	CD20 +	Follicular Lymphoma	Cyclophosphamide, Prednisolone, Rituximab, Vincristine
Sensitivity (+)	CD20 +	Follicular Lymphoma	Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine
Sensitivity (+)	CD20 +	Follicular Lymphoma	Chlorambucil, Mitoxantrone, Prednisolone, Rituximab
Sensitivity (+)	CD20 +	Follicular Lymphoma	Cyclophosphamide, Doxorubicin, Etoposide, Interferon Alpha, Prednisolone, Rituximab
Sensitivity (+)	CD20 +	Non-Hodgkin Lymphoma	Rituximab
Sensitivity (+)	CD20 +	Follicular Lymphoma	Rituximab
Sensitivity (+)	CD20 +	Non-Hodgkin Lymphoma	Rituximab
Sensitivity (+)	CD20 +	Follicular Lymphoma	Rituximab
Sensitivity (+)	CD20 +	Non-Hodgkin Lymphoma	Rituximab
Sensitivity (+)	CD20 +	Follicular Lymphoma	Rituximab
Sensitivity (+)	CD20 +	Diffuse Large B-Cell Lymphoma	Cyclophosphamide, Doxorubicin, Etoposide, Prednisolone, Rituximab, Vincristine
Sensitivity (+)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Doxorubicin, Etoposide, Prednisolone, Rituximab, Vincristine
Sensitivity (+)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Prednisolone, Rituximab, Vincristine
Sensitivity (+)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Prednisolone, Rituximab, Vincristine
Sensitivity (+)	CD20 +	Non-Hodgkin Lymphoma	Rituximab
Sensitivity (+)	CD20 +	Follicular Lymphoma	Rituximab
Sensitivity (+)	CD117 +	Gastrointestinal Stromal Tumor	Imatinib
Sensitivity (+)	CD117 +	Gastrointestinal Stromal Tumor	Imatinib
Sensitivity (+)	MET Exon 14 (Splice Site)	Non-Small Cell Lung Cancer	Tepotinib
Sensitivity (+)	MET Exon 14 (Deletion)	Non-Small Cell Lung Cancer	Tepotinib
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab deruxtecan
Sensitivity (+)	ER negative, HER2-negative, PR negative	Invasive Breast Carcinoma	Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel, Pembrolizumab
Sensitivity (+)	ER negative, HER2-negative, PR negative	Invasive Breast Carcinoma	Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel, Pembrolizumab
Sensitivity (+)	v::RET	Medullary Thyroid Cancer	Vandetanib
Sensitivity (+)	PML::RARA	APL with PML-RARA	Arsenic trioxide
Sensitivity (+)	PML::RARA	APL with PML-RARA	Arsenic trioxide
Sensitivity (+)	ER negative, HER2-negative, PR negative	Invasive Breast Carcinoma	Sacituzumab govitecan
Sensitivity (+)	v::NTRK1	Any solid tumor	Entrectinib
Sensitivity (+)	v::NTRK2	Any solid tumor	Entrectinib
Sensitivity (+)	v::NTRK3	Any solid tumor	Entrectinib
Sensitivity (+)	ER positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (+)	PR positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (+)	ER positive, PR positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (+)	ER positive, PR positive	Invasive Breast Carcinoma	Letrozole
Sensitivity (+)	ER positive	Invasive Breast Carcinoma	Letrozole
Sensitivity (+)	PR positive	Invasive Breast Carcinoma	Letrozole
Sensitivity (+)	ER positive, PR positive	Invasive Breast Carcinoma	Letrozole
Sensitivity (+)	ER positive	Invasive Breast Carcinoma	Letrozole
Sensitivity (+)	PR positive	Invasive Breast Carcinoma	Letrozole